Amniotics granted key EU patent for its technology platform
Non-Regulatory
June 7, 2023
Amniotics (publ) (Nasdaq Stockholm: AMNI) announced today that the European Patent Office (EPO) has approved a patent application for the company’s stem cell technology platform, including the product candidate PulmoStem™. This patent, no. EP3886880 B1, “Processes and apparatuses for obtaining amniotic fluid mesenchymal stem cells from amniotic fluid and cells derived thereof”, provides Amniotics with exclusive commercial rights in the EU at least until 2040 for the manufacture and use of the neonatal stem cells that Amniotics are developing.
– This EU patent is a strong addition to Amniotics patent portfolio as it covers key concepts including our selection techniques of specific cells and our manufacturing methods that are the basis for Amniotics tissue specific neonatal stem cell technology. The patent includes the product candidate PulmoStem (lung), but is also highly relevant to our other candidates, e.g. CogniStem (brain). We wish to thank our legal associates at Potter Clarkson for making this application successful, says Marcus Larsson, CEO, Amniotics AB.